Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing <i>Enterobacterales</i> Bloodstream Infections and/or Ventilator-Associated Pneumonia?

(1) Background: Piperacillin-tazobactam represents the first-line option for treating infections caused by full- or multi-susceptible <i>Enterobacterales</i> and/or <i>Pseudomonas aeruginosa</i> in critically ill patients. Several studies reported that attaining aggressive pharmacokinetic/pharmacody...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Milo Gatti, Matteo Rinaldi, Tommaso Tonetti, Antonio Siniscalchi, Pierluigi Viale, Federico Pea
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	MDPI AG 2023-12-01
סדרה:	Antibiotics
נושאים:	piperacillin-tazobactam continuous infusion critically ill patients Gram-negative infections joint PK/PD target attainment expert clinical pharmacological advice
גישה מקוונת:	https://www.mdpi.com/2079-6382/12/12/1736
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!